-+ 0.00%
-+ 0.00%
-+ 0.00%
Purple Biotech Presents Preclinical Data On IM1240, Lead Capped Tri-Specific Antibody From CAPTN-3 Platform, In Plenary Oral Session At 38th EORTC-NCI-AACR Symposium
Share
Listen to the news
  • Plenary oral presentation by Mount Sinai immunologist Dr. Amir Horowitz highlights Purple Biotech's CAPTN-3 platform of capped tri-specific antibodies, designed to engage T cells and NK cells against cancers expressing antigens of interest while overcoming inhibitory signals that constrain anti-tumor immunity.
  • CAPTN-3 antibodies combine an NKG2A arm that blocks an inhibitory immune checkpoint with a capped CD3 arm designed to penetrate into solid cancers and activate T cells only within the tumor microenvironment, distinguishing the platform from conventional T-cell engagers that activate T cells before reaching their target.
  • IM1240, targeting 5T4, an oncofetal antigen expressed on a wide range of cancers, demonstrated potent anti-tumor activity in patient-derived lung, head and neck, and bladder cancers resistant to immunotherapy, including a muscle-invasive bladder cancer resistant to enfortumab vedotin plus pembrolizumab.
  • NKG2A engagement is a key contributor to tumor killing, as demonstrated in studies using IM1240 and matched antibody variants in patient-derived cancer specimens, supporting the platform's strategy of targeting both innate and adaptive immune responses.
  • In non-human primates, CD3 capping markedly reduced cytokine release and extended systemic exposure compared with a non-capped variant, with an approximately 8-fold longer half-life and 16-fold greater exposure, further supporting the potential of IM1240 to combine potent anti-tumor activity with a broad therapeutic window.

REHOVOT, Israel, Nov. 20, 2026 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech" or the "Company") (NASDAQ/TASE: PPBT), a biotechnology company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced the presentation of preclinical data on IM1240, the lead capped tri-specific antibody from its CAPTN-3 platform, in a plenary oral session at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2026), being held November 18-20, 2026, in Barcelona, Spain.

CAPTN-3 is Purple Biotech's platform of capped tri-specific antibodies. Each antibody combines three arms in a single molecule: a targeting arm that binds a cancer-associated antigen and can be exchanged to address different cancers; a CD3 arm that engages T cells; and an NKG2A arm that engages NK cells and blocks an inhibitory immune checkpoint. The CD3 arm is capped: it is designed to remain inactive in circulation and to be uncapped by proteases in the tumor microenvironment, confining T-cell activation to the cancer and, based on preclinical data, expanding the therapeutic window compared with non-capped T-cell engagers. IM1240, the platform's lead candidate, targets 5T4.

The findings were presented in a plenary oral session by Amir Horowitz, Ph.D., Associate Professor of Immunology and Immunotherapy and Oncological Sciences at the Icahn School of Medicine at Mount Sinai, and a member of the Marc and Jennifer Lipschultz Precision Immunology Institute and The Tisch Cancer Institute.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending